Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. received FDA clearance to begin a registrational Phase 2b trial of its SkinJect microneedle patch in patients with Gorlin Syndrome, advancing the treatment toward …
ICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received authorization from Abu Dhabi health regulators to proceed with a Phase 2a trial of Teverelix in women with symptomatic endometriosis, advancing …
Medicus Wins UAE Clearance for Genomics-Guided Drug Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) received U.S. Food and Drug Administration authorization to begin a registrational Phase 2b study of its SkinJect treatment in patients with Gorlin …
FDA Clears Medicus to Start Gorlin Syndrome Drug Study Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported that its experimental drug latarcibart reduced the median annualized bleeding rate by 81% in a 16-patient Phase 1/2 study, supporting the company’s decision …
Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study Read More
MALVERN, PA — MAXONA Pharmaceuticals has received U.S. Food and Drug Administration clearance to begin a Phase 2 clinical trial of its investigational non-opioid pain therapy, advancing the company’s effort …
FDA Clears MAXONA Pain Drug for Phase 2 Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is moving toward activation of a redesigned Phase 2 Teverelix trial after receiving FDA feedback and central ethics approval, cutting planned enrollment …
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review Read More
WASHINGTON, D.C. — The Department of Veterans Affairs and the Department of Health and Human Services signed an agreement to coordinate research and regulatory efforts aimed at accelerating the evaluation …
VA, HHS Expand Psychedelic Research for Veterans Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) plans to test its Teverelix drug candidate in about 126 patients after receiving FDA feedback and central ethics approval for a redesigned …
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds Read More
WAYNE, PA — Clinical trial sponsors using risk-based quality management (RBQM) may shorten oncology trial timelines by as much as 19% while generating returns of up to 23 times their …
CluePoints Study Links Risk-Based Trial Oversight to Faster Drug Development Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has completed enrollment in its pivotal Phase 3 Alzheimer’s disease trial, positioning the biotechnology company for two planned U.S. regulatory submissions beginning …
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial Read More